<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[26, 35] patients with chronic heart failure after myocardial infarction.<br>[53, 60] patients with heart failure (HF)<br>[92, 106] patients with class II to IV HF and ejection fraction <35%.<br>[135, 155] 330 patients intended for enrollment, 23 were randomized (MARVEL-1) before stopping the study for financial reasons.<br></td>
<td width=33%>
[26, 35] patients with chronic heart failure after myocardial infarction.<br>[53, 61] patients with heart failure (HF).<br>[92, 106] patients with class II to IV HF and ejection fraction <35%.<br>[134, 155] Of 330 patients intended for enrollment, 23 were randomized (MARVEL-1) before stopping the study for financial reasons.<br>[275, 282] HF patients with chronic postinfarction cardiomyopathy,<br></td>
<td width=33%>
[26, 35] patients with chronic heart failure after myocardial infarction.<br>[53, 61] patients with heart failure (HF).<br>[92, 106] patients with class II to IV HF and ejection fraction <35%.<br>[134, 155] Of 330 patients intended for enrollment, 23 were randomized (MARVEL-1) before stopping the study for financial reasons.<br>[275, 282] HF patients with chronic postinfarction cardiomyopathy,<br>[332, 337] HF patients with postinfarction cardiomyopathy<br></td>
</tr>
